Miki Yamaguchi
Overview
Explore the profile of Miki Yamaguchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
1051
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sumi T, Ikeda T, Arioka K, Sakuma Y, Yamaguchi M, Ishigooka T, et al.
Transl Lung Cancer Res
. 2024 Nov;
13(10):2847-2852.
PMID: 39507033
Background: Lung cancer remains the primary cause of cancer-related mortality globally, treated using immune checkpoint inhibitors (ICIs), which are introducing new therapeutic potential and complexities, including severe immune-related adverse events...
2.
Kuba S, Soutome S, Hagiwara Y, Kikawa Y, Iwamoto T, Sangai T, et al.
Jpn J Clin Oncol
. 2024 Oct;
55(2):172-175.
PMID: 39354670
Stomatitis, which is a common side effect of chemotherapy, currently lacks a standardized approach for its prevention. Therefore, this multicenter, randomized, open-label, controlled phase III trial aims to assess the...
3.
Nakayama T, Niikura N, Yamanaka T, Yamamoto M, Matsuura K, Inoue K, et al.
Breast Cancer
. 2024 Sep;
31(6):1184.
PMID: 39302559
No abstract available.
4.
Ono M, Hayashizaki Y, Orihara S, Kitamizu M, Hamada C, Yamaguchi M, et al.
Nutrition
. 2024 Sep;
127:112555.
PMID: 39226629
Objective: To assess the relationship between meal consumption frequency and assisted reproductive technology (ART) outcomes among female patients with infertility. Research Methods & Procedures: This cohort study was conducted from...
5.
Yamaguchi M, Hirai S, Idogawa M, Sumi T, Uchida H, Sakuma Y
Int J Mol Sci
. 2024 Aug;
25(16).
PMID: 39201435
Few effective treatments are available for small cell lung cancer (SCLC), indicating the need to explore new therapeutic options. Here, we focus on an antibody-drug conjugate (ADC) targeting the L1...
6.
Nakayama T, Niikura N, Yamanaka T, Yamamoto M, Matsuura K, Inoue K, et al.
Breast Cancer
. 2024 Aug;
31(6):1167-1175.
PMID: 39133378
We provide updated results (median follow-up duration: 20.4 months) of a retrospective study on the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2-positive (HER2+)...
7.
Sakuma Y, Hirai S, Yamaguchi M, Idogawa M
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000337
Few efficacious treatment options are available for patients with small cell lung carcinoma (SCLC), indicating the need to develop novel therapeutic approaches. In this study, we explored kinesin family member...
8.
Yoshinami T, Nagai S, Hattori M, Okamura T, Watanabe K, Nakayama T, et al.
Breast Cancer
. 2024 Apr;
31(4):621-632.
PMID: 38642245
Background: A recent large real-world study conducted in the United States reported the effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2- advanced breast cancer (ABC). However, local clinical practice and...
9.
Niikura N, Yamanaka T, Nomura H, Shiraishi K, Kusama H, Yamamoto M, et al.
NPJ Breast Cancer
. 2023 Oct;
9(1):82.
PMID: 37821514
Therapeutic options for breast cancer patients with brain metastases (BM)/leptomeningeal carcinomatosis (LMC) are limited. Here, we report on the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth...
10.
Sakuma Y, Hirai S, Sumi T, Niki T, Yamaguchi M
Biochem Biophys Res Commun
. 2023 Aug;
678:84-89.
PMID: 37619315
EGFR-mutant lung adenocarcinoma (LUAD) mostly depends on EGFR for survival and consequently responds well to EGFR inhibitors. However, resistance to the drugs develops almost universally during treatment. We previously demonstrated...